Drug Profile

VRON 0300

Alternative Names: VRON-0300

Latest Information Update: 26 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ocean Biomedical - Virion Therapeutics (JV); Virion Therapeutics
Class Cancer vaccines; Immunotherapies
Mechanism of Action Checkpoint kinase modulators; Immunostimulants; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

26 Jun 2025 Virion Therapeutics plans a phase Ib trial for Solid tumours (Late-stage disease) in Q1 2026 (Virion Therapeutics pipeline, June 2025)
14 Nov 2023 Ocean Biomedical announces intention to submit IND for Solid tumours within the next 9 months
19 Oct 2023 Preclinical trials in Solid tumours in USA (Parenteral) (Virion Therapeutics pipeline, October 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com